Nerve Stimulation Device Trial Cleared for Cachexia
Houston patients with pancreatic cancer may soon enroll in a new study testing a noninvasive device to treat cachexia.
Updated on Oct. 7, 2026 in Cancer
Live Poll
Should medical research prioritize noninvasive device-based treatments for cancer-related symptoms?
Regulators have approved the first human trial of a nerve-stimulation device designed to address cancer-related cachexia, a condition characterized by severe muscle and weight loss. The initial trial will take place at MD Anderson Cancer Center in Houston.
Why it matters
Cachexia currently has no FDA-approved treatments and often forces patients to stop chemotherapy early due to extreme physical decline. This study explores whether modulating the vagus nerve can manage this condition when traditional nutritional interventions fail.
The clinical trial, involving 10 pancreatic cancer patients at MD Anderson Cancer Center, is designed to evaluate device safety and usability during an eight-week lead-in phase. These findings are preliminary, as the efficacy of the stimulation remains under investigation.
The players
MD Anderson Cancer Center
A Houston-based comprehensive cancer center that is hosting the clinical trial for pancreatic cancer patients.
National Cancer Institute
A federal agency that funds cancer research and is a primary sponsor of the upcoming clinical trial.
OnVagus
A medical device company developing noninvasive nerve-stimulation technology for chronic health conditions.
The details
The OnVagus device uses noninvasive electrical stimulation delivered through the skin to modulate the vagus nerve. By targeting this nerve, researchers aim to regulate the systemic inflammatory and metabolic pathways that drive cachexia. If the initial safety trial is successful, the study will expand into a larger, double-blinded investigation.
Timeline
A preclinical study on vagal blockade was published in 2025.
The first patient is expected to enroll in the trial in October 2026.
The safety lead-in trial will last for eight weeks.
Health Landscape
This trial represents a shift in oncology supportive care by applying nerve-modulation technology, previously successful in neurological disorders, to address systemic wasting. It follows a historical arc of seeking non-pharmacological interventions for cancer symptoms that currently lack standard care.
Patients experiencing involuntary muscle loss should speak with their oncology team to determine if they meet the criteria for ongoing clinical trials at MD Anderson Cancer Center. It is important to discuss whether experimental non-drug interventions align with your current treatment plan.
The takeaway
Cachexia represents a major barrier to continuing life-extending chemotherapy for many patients. Patients struggling with persistent, involuntary weight loss should raise concerns about their physical decline with their oncologist to track trends and evaluate new support options.
Further reading
Learn more about the latest innovations in Cancer care and clinical research developments.
Live Poll
Should medical research prioritize noninvasive device-based treatments for cancer-related symptoms?
